File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The outcomes of systemic treatment in recurrent hepatocellular carcinomas following liver transplants

TitleThe outcomes of systemic treatment in recurrent hepatocellular carcinomas following liver transplants
Authors
KeywordsHepatocellular carcinoma
Liver transplant
Recurrence
Survival
Systemic therapy
Issue Date2021
PublisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/12325
Citation
Advances in Therapy, 2021, v. 38 n. 7, p. 3900-3910 How to Cite?
AbstractBackground: Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging. Most clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. We aimed to assess the outcomes in using various systemic therapies in patients with post-LT recurrence. Methods: Consecutive patients with HCC and recurrences following LT at a large tertiary centre from 2005 to 2018 were reviewed. Overall survival (OS), response rates and adverse events (AEs) were analysed. Results: Forty-three consecutive patients with a recurrence of HCC following LT were identified from 2005 to 2018. Median OS from diagnosis of recurrence was 17 months (CI 11.3, 22.7). Early recurrence within 12 months of transplant was associated with a significantly worse median survival of 10 months (CI 8.5, 11.4) compared to 26 months (CI 18.8, 33.2) when recurrences occurred after 12 months from transplant (p < 0.001) with a hazard ratio of 0.104 (log-rank test, p < 0.001). A total of 41 patients had received systemic therapies and 79.1% of them were on sorafenib as the first-line treatment. Among these patients treated with sorafenib, median OS from recurrence was 14 months (CI 7.3, 20.7). Hand-foot syndrome (34.7%) was most common among AEs followed by diarrhoea (26.7%). Overall, AEs led to dose interruptions in 8.8% of patients. Notably, 47.1% of patients received subsequent lines of systemic therapies after sorafenib. Conclusions: Early recurrence within 1 year from transplant was the most significant risk factor. Treatment efficacy and adverse events and tolerability of sorafenib were comparable with those in the setting of advanced HCC without transplant.
Persistent Identifierhttp://hdl.handle.net/10722/304698
ISSN
2020 Impact Factor: 3.845
2020 SCImago Journal Rankings: 1.097
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, BCW-
dc.contributor.authorChiu, J-
dc.contributor.authorShing, K-
dc.contributor.authorKwok, GGW-
dc.contributor.authorTang, V-
dc.contributor.authorLeung, R-
dc.contributor.authorMa, KW-
dc.contributor.authorShe, WH-
dc.contributor.authorTsang, J-
dc.contributor.authorChan, A-
dc.contributor.authorCheung, TT-
dc.contributor.authorLo, CM-
dc.contributor.authorYau, T-
dc.date.accessioned2021-10-05T02:33:52Z-
dc.date.available2021-10-05T02:33:52Z-
dc.date.issued2021-
dc.identifier.citationAdvances in Therapy, 2021, v. 38 n. 7, p. 3900-3910-
dc.identifier.issn0741-238X-
dc.identifier.urihttp://hdl.handle.net/10722/304698-
dc.description.abstractBackground: Treatment of hepatocellular carcinoma (HCC) recurrences following liver transplant (LT) is challenging. Most clinical trials of systemic therapies for advanced HCC excluded patients with any history of organ transplant. We aimed to assess the outcomes in using various systemic therapies in patients with post-LT recurrence. Methods: Consecutive patients with HCC and recurrences following LT at a large tertiary centre from 2005 to 2018 were reviewed. Overall survival (OS), response rates and adverse events (AEs) were analysed. Results: Forty-three consecutive patients with a recurrence of HCC following LT were identified from 2005 to 2018. Median OS from diagnosis of recurrence was 17 months (CI 11.3, 22.7). Early recurrence within 12 months of transplant was associated with a significantly worse median survival of 10 months (CI 8.5, 11.4) compared to 26 months (CI 18.8, 33.2) when recurrences occurred after 12 months from transplant (p < 0.001) with a hazard ratio of 0.104 (log-rank test, p < 0.001). A total of 41 patients had received systemic therapies and 79.1% of them were on sorafenib as the first-line treatment. Among these patients treated with sorafenib, median OS from recurrence was 14 months (CI 7.3, 20.7). Hand-foot syndrome (34.7%) was most common among AEs followed by diarrhoea (26.7%). Overall, AEs led to dose interruptions in 8.8% of patients. Notably, 47.1% of patients received subsequent lines of systemic therapies after sorafenib. Conclusions: Early recurrence within 1 year from transplant was the most significant risk factor. Treatment efficacy and adverse events and tolerability of sorafenib were comparable with those in the setting of advanced HCC without transplant.-
dc.languageeng-
dc.publisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/12325-
dc.relation.ispartofAdvances in Therapy-
dc.subjectHepatocellular carcinoma-
dc.subjectLiver transplant-
dc.subjectRecurrence-
dc.subjectSurvival-
dc.subjectSystemic therapy-
dc.titleThe outcomes of systemic treatment in recurrent hepatocellular carcinomas following liver transplants-
dc.typeArticle-
dc.identifier.emailLi, BCW: bryanli@hku.hk-
dc.identifier.emailChiu, J: jwychiu@hku.hk-
dc.identifier.emailShing, K: kitshing@hku.hk-
dc.identifier.emailTang, V: vyftang@hku.hk-
dc.identifier.emailChan, A: acchan@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityChiu, J=rp01917-
dc.identifier.authorityMa, KW=rp02758-
dc.identifier.authorityChan, A=rp00310-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.authorityYau, T=rp01466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12325-021-01800-z-
dc.identifier.pmid34061324-
dc.identifier.scopuseid_2-s2.0-85107549236-
dc.identifier.hkuros326276-
dc.identifier.volume38-
dc.identifier.issue7-
dc.identifier.spage3900-
dc.identifier.epage3910-
dc.identifier.isiWOS:000656771500002-
dc.publisher.placeNew Zealand-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats